FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178958087> ?p ?o ?g. }

• W3178958087 endingPage "e2116572" @default.
• W3178958087 startingPage "e2116572" @default.
• W3178958087 abstract "Seroprevalence studies complement data on detected cases and attributed deaths in assessing the cumulative spread of the SARS-CoV-2 virus.To estimate seroprevalence of SARS-CoV-2 antibodies in patients receiving dialysis and adults in the US in January 2021 before the widespread introduction of COVID-19 vaccines.This cross-sectional study used data from the third largest US dialysis organization (US Renal Care), which has facilities located nationwide, to estimate SARS-CoV-2 seroprevalence among US patients receiving dialysis. Remainder plasma (ie, plasma that would have otherwise been discarded) of all patients receiving dialysis at US Renal Care facilities from January 1 to 31, 2021, was tested for SARS-CoV-2 antibodies. Patients were excluded if they had a documented dose of SARS-CoV-2 vaccination or if a residence zip code was missing from electronic medical records. Crude seroprevalence estimates from this sample (January 2021) were standardized to the US adult population using the 2018 American Community Survey 1-year estimates and stratified by age group, sex, self-reported race/ethnicity, neighborhood race/ethnicity composition, neighborhood income level, and urban or rural status. These data and case detection rates were then compared with data from a July 2020 subsample of patients who received dialysis at the same facilities.Age, sex, race/ethnicity, and region of residence as well as neighborhood race/ethnicity composition, poverty, population density, and urban or rural status.The spike protein receptor-binding domain total antibody assay (Siemens Healthineers; manufacturer-reported sensitivity of 100% and specificity of 99.8%) was used to estimate crude SARS-CoV-2 seroprevalence in the unweighted sample, and then the estimated seroprevalence rates for the US dialysis and adult populations were calculated, adjusting for age, sex, and region.A total of 21 464 patients (mean [SD] age, 63.1 [14.2] years; 12 265 men [57%]) were included in the unweighted sample from January 2021. The patients were disproportionately older (aged 65-79 years, 7847 [37%]; aged ≥80 years, 2668 [12%]) and members of racial/ethnic minority groups (Hispanic patients, 2945 [18%]; non-Hispanic Black patients, 4875 [29%]). Seroprevalence of SARS-CoV-2 antibodies was 18.9% (95% CI, 18.3%-19.5%) in the sample, with a seroprevalence of 18.7% (95% CI, 18.1%-19.2%) standardized to the US dialysis population, and 21.3% (95% CI, 20.3%-22.3%) standardized to the US adult population. In the unweighted sample, younger persons (aged 18-44 years, 25.9%; 95% CI, 24.1%-27.8%), those who self-identified as Hispanic or living in Hispanic neighborhoods (25.1%; 95% CI, 23.6%-26.4%), and those living in the lowest-income neighborhoods (24.8%; 95% CI, 23.2%-26.5%) were among the subgroups with the highest seroprevalence. Little variability was observed in seroprevalence by geographic region, population density, and urban or rural status in the January 2021 sample (largest regional difference, 1.2 [95% CI, 1.1-1.3] higher odds of seroprevalence in residents of the Northeast vs West).In this cross-sectional study of patients receiving dialysis in the US, fewer than 1 in 4 patients had evidence of SARS-CoV-2 antibodies 1 year after the first case of SARS-CoV-2 infection was detected in the US. Results standardized to the US population indicate similar prevalence of antibodies among US adults. Vaccine introduction to younger individuals, those living in neighborhoods with a large population of racial/ethnic minority residents, and those living in low-income neighborhoods may be critical to disrupting the spread of infection." @default.
• W3178958087 created "2021-07-19" @default.
• W3178958087 creator A5030519205 @default.
• W3178958087 creator A5034725039 @default.
• W3178958087 creator A5034939991 @default.
• W3178958087 creator A5041207649 @default.
• W3178958087 creator A5050977311 @default.
• W3178958087 creator A5054537002 @default.
• W3178958087 creator A5058219904 @default.
• W3178958087 creator A5064302758 @default.
• W3178958087 creator A5066090611 @default.
• W3178958087 creator A5072020289 @default.
• W3178958087 creator A5072986625 @default.
• W3178958087 creator A5081761130 @default.
• W3178958087 creator A5086447542 @default.
• W3178958087 date "2021-07-12" @default.
• W3178958087 modified "2023-09-24" @default.
• W3178958087 title "Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic" @default.
• W3178958087 cites W3008443627 @default.
• W3178958087 cites W3044468596 @default.
• W3178958087 cites W3082342835 @default.
• W3178958087 cites W3089010823 @default.
• W3178958087 cites W3090135427 @default.
• W3178958087 cites W3092301564 @default.
• W3178958087 cites W3092982396 @default.
• W3178958087 cites W3093038587 @default.
• W3178958087 cites W3093046487 @default.
• W3178958087 cites W3093231763 @default.
• W3178958087 cites W3094968263 @default.
• W3178958087 cites W3096786678 @default.
• W3178958087 cites W3101046181 @default.
• W3178958087 cites W3108096807 @default.
• W3178958087 cites W3108582220 @default.
• W3178958087 cites W3111021405 @default.
• W3178958087 cites W3111752899 @default.
• W3178958087 cites W3112547455 @default.
• W3178958087 cites W3116267744 @default.
• W3178958087 cites W3121286195 @default.
• W3178958087 cites W3122600273 @default.
• W3178958087 cites W3128397309 @default.
• W3178958087 cites W3165838540 @default.
• W3178958087 doi "https://doi.org/10.1001/jamanetworkopen.2021.16572" @default.
• W3178958087 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8276082" @default.
• W3178958087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34251441" @default.
• W3178958087 hasPublicationYear "2021" @default.
• W3178958087 type Work @default.
• W3178958087 sameAs 3178958087 @default.
• W3178958087 citedByCount "11" @default.
• W3178958087 countsByYear W31789580872021 @default.
• W3178958087 countsByYear W31789580872022 @default.
• W3178958087 countsByYear W31789580872023 @default.
• W3178958087 crossrefType "journal-article" @default.
• W3178958087 hasAuthorship W3178958087A5030519205 @default.
• W3178958087 hasAuthorship W3178958087A5034725039 @default.
• W3178958087 hasAuthorship W3178958087A5034939991 @default.
• W3178958087 hasAuthorship W3178958087A5041207649 @default.
• W3178958087 hasAuthorship W3178958087A5050977311 @default.
• W3178958087 hasAuthorship W3178958087A5054537002 @default.
• W3178958087 hasAuthorship W3178958087A5058219904 @default.
• W3178958087 hasAuthorship W3178958087A5064302758 @default.
• W3178958087 hasAuthorship W3178958087A5066090611 @default.
• W3178958087 hasAuthorship W3178958087A5072020289 @default.
• W3178958087 hasAuthorship W3178958087A5072986625 @default.
• W3178958087 hasAuthorship W3178958087A5081761130 @default.
• W3178958087 hasAuthorship W3178958087A5086447542 @default.
• W3178958087 hasBestOaLocation W31789580871 @default.
• W3178958087 hasConcept C126322002 @default.
• W3178958087 hasConcept C137403100 @default.
• W3178958087 hasConcept C144024400 @default.
• W3178958087 hasConcept C149923435 @default.
• W3178958087 hasConcept C159654299 @default.
• W3178958087 hasConcept C19165224 @default.
• W3178958087 hasConcept C194828623 @default.
• W3178958087 hasConcept C203014093 @default.
• W3178958087 hasConcept C2776269092 @default.
• W3178958087 hasConcept C2778494684 @default.
• W3178958087 hasConcept C2779134260 @default.
• W3178958087 hasConcept C2779978075 @default.
• W3178958087 hasConcept C2908647359 @default.
• W3178958087 hasConcept C3008058167 @default.
• W3178958087 hasConcept C45189115 @default.
• W3178958087 hasConcept C524204448 @default.
• W3178958087 hasConcept C71924100 @default.
• W3178958087 hasConcept C89623803 @default.
• W3178958087 hasConcept C99454951 @default.
• W3178958087 hasConceptScore W3178958087C126322002 @default.
• W3178958087 hasConceptScore W3178958087C137403100 @default.
• W3178958087 hasConceptScore W3178958087C144024400 @default.
• W3178958087 hasConceptScore W3178958087C149923435 @default.
• W3178958087 hasConceptScore W3178958087C159654299 @default.
• W3178958087 hasConceptScore W3178958087C19165224 @default.
• W3178958087 hasConceptScore W3178958087C194828623 @default.
• W3178958087 hasConceptScore W3178958087C203014093 @default.
• W3178958087 hasConceptScore W3178958087C2776269092 @default.
• W3178958087 hasConceptScore W3178958087C2778494684 @default.
• W3178958087 hasConceptScore W3178958087C2779134260 @default.
• W3178958087 hasConceptScore W3178958087C2779978075 @default.
• W3178958087 hasConceptScore W3178958087C2908647359 @default.

• next